Loading
A phase 3 trial of Izalontamab brengitecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) is a phase 3 interventional study registered as NCT06382129 by Sichuan Baili Pharmaceutical Co., Ltd., with 698 participants enrolled, started 2024-05-17 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, Docetaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SystImmune / Sichuan Biokin, Docetaxel, Cytotoxic chemotherapy.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SystImmune / Sichuan Biokin, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.